Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam

Journal of Clinical Microbiology

Volumn 44, Issue 7, 2006, Pages 2333-2337

  Caws, M ^a   Duy, Phan Minh ^a   Tho, Dau Quang ^a   Lan, Nguyen Thi Ngoc ^b   Hoa, Dai Viet ^b   Farrar, Jeremy ^a  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b Pham Ngoc Thach Hospital   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CLINICAL LABORATORY; GENE MUTATION; HOSPITAL; HUMAN; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TUBERCULOSIS; TUBERCULOSIS CONTROL; VIET NAM;

MYCOBACTERIUM TUBERCULOSIS;

EID: 33746216212     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00330-06     Document Type: Article

References (36)

1. Baker, L. V., T. J. Brown, O. Maxwell, A. L. Gibson, Z. Fang, M. D. Yates, and F. A. Drobniewski. 2005. Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates from England and Wales reveals the phylogenctic significance of the ahpC -46A polymorphism. Antimicrob. Agents Chemother. 49:1455-1464.
2. Bertrand, T., N. A. Eady, J. N. Jones, Jesmin, J. M. Nagy, B. Jamart-Gregoire, E. L. Raven, and K. A. Brown. 2004. Crystal structure of Mycobacterium tuberculosis catalase-peroxidase. J. Biol. Chem. 279:38991-38999.
3. Buu, T. N., K. Lonnroth, and H. T. Quy. 2003. Initial defaulting in the National Tuberculosis Programme in Ho Chi Minh City, Vietnam: a survey of extent, reasons and alternative actions taken following default. Int. J. Tuberc. Lung Dis. 7:735-741.
4. Deretic, V., J. Song, and E. Pagan-Ramos. 1997. Loss of oxyR in Mycobacterium tuberculosis. Trends Microbiol. 5:367-372.
5. DeRiemer, K., L. Garcia-Garcia, M. Bohadilla-del-Valle, M. Palacios-Martinez, A. Martinez-Gamboa, P. M. Small, J. Sifuentes-Osornio, and A. Ponce-de-Leon. 2005. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 365:1239-1245.
6. Dye, C., and M. A. Espinal. 2001. Will tuberculosis become resistant to all antibiotics? Proc. Biol. Sci. 268:45-52.
7. Espinal, M. A. 2003. Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int. J. Tuberc. Lung Dis. 7:607-608.
8. Heep, M., B. Brandstatter, U. Rieger, N. Lehn, E. Richter, S. Rusch-Gerdes, and S. Niemann. 2001. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 39:107-110.
9. Heep, M., U. Rieger, D. Beck, and N. Lehn. 2000. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:1075-1077.
10. Herrera, L., S. Jimenez, A. Valverde, M. A. Garcia-Aranda, and J. A. Saez-Nieto. 2003. Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996-2001). Description of new mutations in the rpoB gene and review of the literature. Int. J. Antimicrob. Agents 21:403-408.
11. Hirano, K., C. Abe, and M. Takahashi. 1999. Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay. J. Clin. Microbiol. 37:2663-2666.
12. Huong, N. T., H. D. Duong, N. V. Co, H. T. Quy, L. B. Tung, M. Bosman, A. Gebhardt, J. P. Velema, J. F. Broekmans, and M. W. Borgdorff. 2005. Establishment and development of the National Tuberculosis Control Programme in Vietnam. Int. J. Tuberc. Lung Dis. 9:151-156.
13. Jindani, A., A. J. Nunn, and D. A. Enarson. 2004. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 364:1244-1251.
14. Kapur, V., L.-L. Li, S. Iordanescu, M. R. Hamrick, A. Wanger, B. N. Kreiswirth, and J. M. Musser, 1994. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J. Clin. Microbiol. 32:1095-1098.
15. Kelley, C. L., D. A. Rouse, and S. L. Morris. 1997. Analysis of ahpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41:2057-2058.
16. Khan, K., P. Muennig, M. Behta, and J. G. Zivin. 2002. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N. Engl. J. Med. 347:1850-1859.
17. Lan, N. T. N., M. F. Lademarco, N. J. Binkin, L. B. Tung, H. T. Quy, and N. V. Cj. 2001. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard rctreatment regimen in Ho Chi Minh City, Vietnam. Int. J. Tuberc. Lung Dis. 5:575-578.
18. Lavender, C., M. Globan, A. Sievers, H. Billman-Jacobe, and J. Fyfe. 2005. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Australia. Antimicrob. Agents Chemother. 49:4068-4074.
19. Lonnroth, K., K. Lambregts, D. T. Nhien, H. T. Quy, and V. K. Diwan. 2000. Privale pharmacies and tuberculosis conlrol: a survey of case detection skills and reported anti-tuberculosis drug dispensing in private pharmacies in Ho Chi Minh City, Vietnam. Int. J. Tuberc. Lung Dis. 4:1052-1059.
20. Lonnroth, K., L. M. Thuong, K. Lambregts, H. T. Quy, and V. K. Diwan. 2003. Private tuberculosis care provision associated with poor treatment outcome: comparative study of a semi-private lung clinic and the NTP in two urban districts in Ho Chi Minh City, Vietnam. National Tuberculosis Programme. Int. J. Tuberc. Lung Dis. 7:165-171.
21. Marttila, H. J., H. Soini, P. Huovinen, and M. K. Viljanen. 1996. katG mutations in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from Finnish patients. Antimicrob. Agents Chemother. 40:2187-2189.
22. Mokrousov, I., N. V. Bhanu, P. N. Suffys, G. V. Kadival, S. F. Yap, S. N. Cho, A. M. Jordaan, O. Narvskaya, U. B. Singh, H. M. Gomes, H. Lee, S. P. Kulkarni, K. C. Lim, B. K. Khan, D. van Soolingen, T. C. Victor, and L. M. Schouls. 2004. Multicenter evaluation of reverse line blot assay for detection of drug resistance in Mycobacterium tuberculosis clinical isolates. J. Microbiol. Methods 57:323-335.
23. Plant, A. J., R. E. Watkins, N. Motus, W. Jones, T. O'Rourke, J. Streeton, and B. Gushulak. 2005. Results of tuberculosis screening in applicants for migration in Vietnam and Cambodia. Int. J. Tuberc. Lung Dis. 9:157-163.
24. Quy, H. T., N. T. Lan, M. W. Borgdorff, J. Grosset, P. D. Linh, L. B. Tung, D. van Soolingen, M. Raviglione, N. V. Co, and J. Broekmans. 2003. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Int. J. Tuberc. Lung Dis. 7:631-636.
25. Ramaswamy, S. V., R. Reich, S. J. Dou, L. Jasperse, X. Pan, A. Wanger, T. Quitugua, and E. A. Graviss. 2003. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:1241-1250.
26. Rouse, D. A., J. A. DeVito, Z. Li, H. Byer, and S. L. Morris. 1996. Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase-peroxidase activities and isoniazid resistance. Mol. Microbiol. 22:583-592.
27. Rozwarski, D. A., G. A. Grant, D. H. Barton, W. R. Jacobs, Jr., and J. C. Sacchettini. 1998. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279:98-102.
28. Silva, M. S. N., S. G. Senna, M. O. Ribeiro, A. R. M. Valim, M. A. Telles, A. Kritski, G. P. Morlock, R. C. Cooksey, A. Zaha, and M. L. R. Rossetti. 2003. Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J. Clin. Microbiol. 41:4471-4474.
29. Telenti, A., N. Honore, C. Bernasconi, J. March, A. Ortega, B. Heym, H. Takiff, and S. Cole. 1997. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J. Clin. Microbiol. 35:719-723.
30. Thorson, A., N. P. Hoa, N. H. Long, P. Allebeck, and V. K. Diwan, 2004. Do women with tuberculosis have a lower likelihood of getting diagnosed? Prevalence and case detection of sputum smear positive pulmonary TB, a population-based study from Vietnam. J. Clin. Epidemiol. 57:398-402.
31. van Soolingen, D., P. E. de Haas, H. R. van Doorn, E. Kuijper, H. Rinder, and M. W. Borgdorff. 2000. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J. Infect. Dis. 182:1788-1790.
32. Ward, H. A., D. D. Marciniuk, V. H. Hoeppner, and W. Jones. 2005. Treatment outcome of multidrug-resistant tuberculosis among Vietnamese immigrants. Int. J. Tuberc. Lung Dis. 9:164-169.
33. Wengenack, N. L., J. R. Uhl, A. L. St Amand, A. J. Tomlinson, L. M. Benson, S. Naylor, B. C. Kline, F. R. Cockerill III, and F. Rusnak. 1997. Recombinant Mycobacterium tuberculosis KatG(S315T) is a competent catalase-peroxidase with reduced activity toward isoniazid. J. Infect. Dis. 176:722-727.
34. Wilson, T. M., G. W. de Lisle, and D. M. Collins. 1995. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol. Microbiol. 15:1009-1015.
35. World Health Organization. 1997. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD global project on drug resistance surveillance, 1994-1997. WHO/tb/97.229. World Health Organization, Geneva, Switzerland.
36. World Health Organization. 2002. Global TB control: surveillance, planning, financing, 2002. World Health Organization, Geneva, Switzerland.